Alzheimer's Treatment Composition Reducing Aβ and Tau Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are limited and provide only marginal relief, with no cure available, and the underlying causes of the disease, particularly the deposition of Aβ protein and tau protein, are not fully understood, leading to significant cognitive decline and caregiver dependency.
Innovation Solution
A composition comprising effective doses of orientin, vitexin, and bergenin, identified through Liquid Chromatography–mass Spectrometry (LC-MS) analysis from Synaptecx-227, which reduces Aβ amyloid fibrils and tau protein accumulations, thereby addressing the disease's pathological mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat Alzheimer's disease, then some marginal relief is provided, but the disease progression continues with no cure available
Solution Approach 1:
The patent changes the chemical parameters of treatment by using specific compounds (orientin, vitexin, bergenin) at defined concentrations (orientin: 10-60 μM, vitexin: 10-60 μM, bergenin: 25-100 μM) to alter the therapeutic mechanism, targeting Aβ and tau pathology directly rather than providing only symptomatic relief
Solution Approach 2:
The invention uses a composite therapeutic approach combining multiple compounds (orientin, vitexin, and bergenin) in specific formulations to achieve synergistic effects against Aβ amyloid fibrils and tau protein, rather than relying on single conventional therapies
2Object-affected harmful factors
If Aβ protein and tau protein deposition is targeted for reduction, then pathological mechanisms are addressed, but treatment complexity increases due to multiple targets
Solution Approach 1:
Each compound in the formulation (orientin, vitexin, bergenin) is designed to perform multiple functions: orientin targets Aβ aggregation, vitexin addresses tau pathology, and bergenin provides neuroprotection, allowing a single formulation to address multiple pathological mechanisms simultaneously
Solution Approach 2:
The treatment approach segments the complex pathology into distinct targets (Aβ amyloid fibrils, tau neurofibrillary tangles, and neuronal vulnerability) and assigns specific compounds to address each target, making the complex disease process manageable through targeted intervention
Data Source
AI summary
Compositions and methods for treating Alzheimer's disease are provided. An exemplary embodiment is a pharmaceutical composition for treatment of Alzheimer's disease in a patient. The pharmaceutical composition includes an effective dose of at least one of orientin, vitexin and bergenin.